[[{“value”:”
Medellin, Colombia: The daily consumption of plant-derived CBD oil relieves agitation, anxiety, depression, and other neuropsychiatric symptoms (NPS) in patients who have Alzheimer’s Disease (AD), according to data published in the journal Medical Cannabis and Cannabinoids.
Colombian researchers assessed the long-term impact of CBD oil on NPS severity in a cohort of 65 patients with AD. Participants in the study were unresponsive to traditional medical treatments. Patients consumed CBD sublingually daily for up to 24 months.
Investigators reported that 95 percent of subjects achieved a reduction in their NPS severity scores by more than 30 percent following three months of CBD treatment. Their improvements were maintained for the length of the study.
The study’s authors concluded: “To the best of our knowledge, this is the first study that evaluated the use of CBD as a treatment in NPS in AD with a sample greater than 50 patients and with a follow-up of more than 1 year. … This study shows that treatment with CBD-rich oil is effective and safe for patients with NPS secondary to AD at a median daily dose of 111 mg, independent of sex, age, time with AD, type of AChEIs [acetylcholinesterase inhibitors], and NPI-Q severity score before CBD treatment. … Further information derived from randomized controlled clinical trials is needed to confirm the findings presented in this article.”
Placebo-controlled clinical trial data has previously demonstrated that the daily administration of oral synthetic THC (dronabinol) and THC-dominant extracts similarly reduces Alzheimer’s-related agitation.
Full text of the study, “Treatment of neuropsychiatric symptoms in Alzheimer’s Disease with a cannabis-based magistral formulation: An open-label prospective cohort study,” appears in Medical Cannabis and Cannabinoids. Additional information on cannabis and Alzheimer’s is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.
“}]]95% of subjects experienced reduced symptoms Read More
